3 completed, 1 terminated, 1 unknown. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Phase 2 | 5 | Completed 3, Terminated 1, Unknown 1 |
Follow milatuzumab: new trials by email Literature Review of milatuzumab trials Research Report on milatuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL hLL1-DOX (IMMU-115) - Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Gilead Sciences | 13 | 2012-08-01 | 2021-10-08 |
| Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma milatuzumab, veltuzumab, Correlative/Special Studies - Lymphoma | Phase 1 / Phase 2 | Completed | Beth Christian | 35 | 2009-09-01 | 2017-02-06 |
| The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) Milatuzumab - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Kaplan Medical Center | 15 | 2009-04-01 | 2010-06-02 |
| Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL milatuzumab - Chronic Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | Gilead Sciences | 19 | 2008-08-01 | 2021-08-16 |
| Phase I/II Study of hLL1 in Multiple Myeloma milatuzumab - Multiple Myeloma, Myeloma, Plasma-Cell | Phase 1 / Phase 2 | Completed | Gilead Sciences | 25 | 2007-01-01 | 2021-08-16 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Plasmacytoma (1) · Waldenstrom Macroglobulinemia (1)
Gilead Sciences (3) · Beth Christian (1) · Kaplan Medical Center (1)
United States (4) · Israel (1)
William Wegener, MD, PhD (2) · Beth Christian, MD (1) · Francois Wilhelm, MD,PhD (1) · Michal Haran, MD (1) · Pius P Maliakal, PhD (1)